Monetizing Digital Twins: What Onix's 'Substack of Bots' Means for Brands, Creators, and Risk Managers
Onix's launch of paid AI "digital twins" of wellness influencers exemplifies a new creator-driven monetization model that blends subscription income with round-the-clock personalized engagement. The model promises revenue and scale for creators and brands but raises clarity, liability, and trust questions-especially when health advice and product endorsements are involved.
Onix is positioning itself as a "Substack of bots," offering subscribers access to AI-driven digital twins of health and wellness influencers that can give bespoke advice and potentially recommend or sell products. This approach accelerates two converging trends: creators monetizing directly from audiences via subscriptions, and AI enabling scaled, personalized interaction without incremental human labor. For businesses, the appeal is clear-recurring revenue, richer engagement signals, and a new channel for branded commerce.
From a commercial perspective, digital twins create multiple monetization levers: subscriptions, pay-per-interaction, affiliate sales, and data-driven upsells. Creators and platforms can capture value while brands gain a persistent presence in users' decision journeys. Licensing and IP arrangements become central: who controls the twin's persona, what claims can it make, how are revenue splits handled, and how is ongoing model training funded and governed? Companies that get these contracts and product designs right can build defensible, repeatable revenue streams.
The model also amplifies regulatory, ethical, and reputational risks. When AI impersonates real people and dispenses health advice, issues around misrepresentation, medical misinformation, and undisclosed endorsements become acute. Firms could face FTC scrutiny over endorsements and advertising disclosures, professional liability if advice causes harm, and privacy concerns if health data are captured and monetized. Transparency, provenance labels, and careful scope limits (e.g., no diagnoses, clear referral to professionals) are not optional-they're risk mitigants.
Business leaders considering similar offerings should prioritize three actions: (1) legal and compliance review up front-covering advertising law, health-care regulation, and IP licensing; (2) product governance-explicit provenance labels, fallback human escalation, bounded claim sets, and monitoring/audit trails for outputs; and (3) commercial design-clear revenue-sharing terms, opt-in data use, and KPIs that balance engagement with trust. Done well, digital twins can be valuable extensions of creator brands; done poorly, they can erode trust and expose firms to costly liabilities.
Original Source
WIRED